TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05945173

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: alcohol/water-based universal adhesive
Description: Composite resin restorations of non-carious cervical lesions will be performed with an alcohol/water-based universal adhesive (Scotchbond Universal Plus; 3M).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: acetone-based universal adhesive
Description: Composite resin restorations of non-carious cervical lesions will be performed with an acetone-based universal adhesive (Gluma Universal Bond; Kulzer).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acetone-based universal adhesive
Description: Composite resin restorations of non-carious cervical lesions will be performed with an acetone-based universal adhesive (Gluma Universal Bond; Kulzer).
Study: NCT05698966

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: we will use reduced dose of acceptable corticosteroids treatment for preterm birth
Description: the two different group will differ in the doses of corticosteroids

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: we will use reduced dose of acceptable corticosteroids treatment for preterm birth
Description: the two different group will differ in the doses of corticosteroids
Study: NCT05375734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab in combination with anlotinib
Description: Tislelizumab：200 mg，ivgtt，d1，Q3W anlotinib： 10mg P.O d1-d14, Q3W
Study: NCT05372692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mesothelin-specific chimeric antigen receptor T cell injection
Description: Autologous T cell injection
Study: NCT06329206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GH2616 Tablets
Description: GH2616 tablets will be given orally
Study: NCT05895240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulinastatin
Description: Nine MiU Ulinastatin in three divided doses 8 hourly for 3-5 days
Study: NCT05818267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: The drug dose that taken by the subject is gradually increased to the maximum dose tolerated by the patient according to individualization. Specifically, the initial dose of 80 mg/day was gradually increased to 120 mg/day (80 mg/day in the first week, 120 mg/day in the second week, and a maximum tolerated dose of 160 mg/day). The maximum tolerated dose is 160 mg/day. The dose is administered once daily in a 4-week cycle (3 weeks of dosing and 1 week of rest) and the maximum dose achieved in the first treatment cycle is maintained.At the discretion of the investigator, regorafenib may be delayed or discontinued. Dose adjustments and interruptions due to toxicity are made according to the recommendations specified in the protocol.
Study: NCT05612425

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safety Behavior Fading for Appearance Concerns
Description: Participants are asked to reduce or eliminate safety behaviors via text message reminders and checklists to monitor progress.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Unhealthy Behavior Fading
Description: Participants are asked to reduce or eliminate unhealthy behaviors via text message reminders and checklists to monitor progress.
Study: NCT02346617

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IFN-γ positive selected T-cells
Description: No intervention
Study: NCT06049030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10516
Description: Oral HIF-2α inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10516
Description: Oral HIF-2α inhibitor
Study: NCT06477913

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rauha
Description: A dual mental health treatment consisting of digitally-administered Cognitive Behavioral Therapy combined with National Board Health and Wellness Coach (NBHWC) trained Mental Health Coaches
Study: NCT05009290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR3680
Description: Treatment group: SHR3680 240 mg orally once daily before or after breakfast, 28 days per cycle for a total of 12 treatment cycles (6 cycles before and 6 cycles following radical prostatectomy).~Goserelin acetate sustained-release depot: 10.8 mg administered subcutaneously into the anterior abdominal wall once every 3 cycles (12 weeks) for a total of 12 cycles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment group ：Placebo 240 mg orally once daily before or after breakfast, 28 days per cycle for a total of 12 treatment cycles (6 cycles before and 6 cycles following radical prostatectomy).~Goserelin acetate sustained-release depot: 10.8 mg administered subcutaneously into the anterior abdominal wall once every 3 cycles (12 weeks) for a total of 12 cycles.
Study: NCT06031363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin Suppository
Description: Patients in the regular dose group are given indomethacin suppository 100 mg anal plug immediately after operation, patients in the low dose group are given indomethacin suppository 50 mg anal plug immediately after operation, and patients in the high dose group are given indomethacin suppository 150 mg anal plug immediately after operation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin Suppository
Description: Patients in the regular dose group are given indomethacin suppository 100 mg anal plug immediately after operation, patients in the low dose group are given indomethacin suppository 50 mg anal plug immediately after operation, and patients in the high dose group are given indomethacin suppository 150 mg anal plug immediately after operation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indomethacin Suppository
Description: Patients in the regular dose group are given indomethacin suppository 100 mg anal plug immediately after operation, patients in the low dose group are given indomethacin suppository 50 mg anal plug immediately after operation, and patients in the high dose group are given indomethacin suppository 150 mg anal plug immediately after operation.
Study: NCT05645939

Intervention type: OTHER
Intervention: Diasgnosis of hypertrophic cardiomyopathy
Description: Patients diagnosed with hypertrophic cardiomyopathy during study period
Study: NCT05400304

Intervention type: DIAGNOSTIC_TEST
Intervention: radiomics
Description: The high-throughput extraction of large amounts of quantitative image features from medical images

Intervention type: DIAGNOSTIC_TEST
Intervention: radiomics
Description: The high-throughput extraction of large amounts of quantitative image features from medical images

Intervention type: DIAGNOSTIC_TEST
Intervention: radiomics
Description: The high-throughput extraction of large amounts of quantitative image features from medical images
Study: NCT05158725

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Colonoscopy
Description: In this arm, subjects will undergo colonoscopy using a standard colonoscope

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Discovery aided colonoscopy
Description: the Discovery is a customized detection support software, developed utilizing AI deep learning technology to support endoscopic lesion detection in the colon. In this arm, a standard colonoscope is used with the Discovery.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Discovery and G-EYE
Description: The G-EYE® Endoscope is a standard colonoscope which is remanufactured by installing the G-EYE® balloon on the distal bending section of the colonoscope. in this arm, the G-EYE® Endoscope is used with the Discovery
Study: NCT05017610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liothyronine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomustine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methimazole
Description: Given PO
Study: NCT05080556

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Treatment in both arms will be administered intravenously (IV) every 21 days (q21D) and for a maximum of 6 cycles in Arm 1 and 12 cycles in Arm 2.
Study: NCT05845853

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: scapular PNF technique
Description: PNF Technique is based on movement patterns to facilitate and correct sensory-motor function,then correct the impaired impulses emerging from proprioceptive receptors in the muscle. Therefore, it decreases pain and improve the strength of muscles.~PNF position renders a greater amount of sensory input coming from the periphery than that in the neutral position .
Study: NCT06312319

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respiratory training
Description: Respiratory training using the EMST 150 device to increase inspiratory and expiratory muscle strength.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Orofacial exercises
Description: The exercises will include activities to improve orofacial structures such as mobility, strength and coordination.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orofacial exercises
Description: The exercises will include activities to improve orofacial structures such as mobility, strength and coordination.
Study: NCT05080556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Treatment in both arms will be administered intravenously (IV) every 21 days (q21D) and for a maximum of 6 cycles in Arm 1 and 12 cycles in Arm 2.
Study: NCT04741490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: PD-1antibodies，200mg ivgtt Q3W

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: 45-55Gy/1.8～2.0Gy
Study: NCT05108558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCH administration
Description: Patients will be randomized 3:1 into the CCH administration arm. After undergoing baseline assessments, this arm will receive up to 8 CCH injections, followed by final assessments 6 weeks later.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control - Crossover to CCH
Description: Patients will be randomized 1:3 into the control arm. After undergoing baseline assessments, control men will not undergo treatments for 6 months. They will then have repeat assessments and receive up to 8 CCH injections. They will then have final assessments performed 6 weeks after treatment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RestoreX
Description: Both treatment arms will incorporate the use of RestoreX for 30-60 minutes daily during CCH administration and continued until 6 weeks after final injection administration.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RestoreX
Description: Both treatment arms will incorporate the use of RestoreX for 30-60 minutes daily during CCH administration and continued until 6 weeks after final injection administration.
Study: NCT04757545

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HM-PRO
Description: The intervention group will have a predetermined consultation appointment planned to assess medical status and symptom control. Seven days prior to the scheduled visit, the patient will receive an electronic invitation via RedCap to complete and send PRO data (HM-PRO). Prior to each appointment PRO data will be evaluated by a nurse from an algorithm deciding one of three tracks for the patients:~1. Worsening in symptoms results in a nurse-led telephone consultation within two days guided by the symptom management manual.~2. Minor changes in patient's symptom assessment result in a nurse-led telephone consultation within seven days using the symptom management manual.~3. Patients that are completely stable in the symptom assessment will receive an electronic answer via min-SP (electronic patient journal) regarding the results and a new appointment, including PRO-data prior to this.
Study: NCT06440551

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TeleSalud Healthy Eating- Physical Activity/Sedentary Behavior (HE-PA/SB)
Description: Participants will meet via telehealth for 4 months (twice a week for 3 months and then once per week for 1 month) for a TeleSalud HE-PA/SB Class, after which they will attend one maintenance meeting per month for 4 months. Weekly, Day 1 (Healthy Eating \& PA-SB Class): Participants will receive a 50-min. healthy eating class. Physical Activity- Sedentary Behavior (PA-SB) Class: By discussing barriers and strategies to overcome barriers, this will help to increase self-efficacy. We will engage in Latino-centered moderate impact (increasing to vigorous) aerobics with Latino or salsa movements and music for 45-50 minutes. Aspects of kickboxing aerobics will be integrated. Goal: Exercise a minimum of 150-250 min./ week of moderate intensity. Weekly, Day 2: PA-SB identical PA-SB to Day 1. Maintenance (Months 5-8): Meetings once/ month for 70 min. for HE/PA-SB class, including 25 min. to discuss diet and PA-SB barriers. Goal: Exercise a minimum of 150-250 min./week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TeleSalud General Health Intervention
Description: Weekly: Participants will meet via telehealth for 4 months (twice a week for 3 months and then once per week for 1 month) for a TeleSalud General Heath Class, after which they will attend one maintenance meeting per month for 4 months. Participants will meet and discuss general health topics (not diet or PA). Examples of the general health topics are: Back Pain, Muscle Strains, Alcohol Use, Stress \& Coping, Oral and Dental Health, Safety Tips, Emergency Preparedness. The content is relevant to Latinos, and information is focused on Latino men. Maintenance (Months 5-8): Participants will meet via telehealth once/ month for 70 min. to discuss general health topics. To enhance motivation to complete the study and assessments, this group will receive a copy of the TeleSalud HE-PA/SB intervention manual and related materials after the maintenance period ends.
Study: NCT05064566

Intervention type: DEVICE
Intervention: caries assessment
Description: clinical visual examination (ICDAS II), digital io radiography, near infrared light transillumination (NIR-LT), and laser fluorescence (LF), and micro-CT images.
Study: NCT06516276

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile App M.I.O
Description: This mobile app provides patients with access to various resources and therapies focused on nutrition, exercise, and emotional well-being. The main objective is to measure the quality of life of the app users through validated questionnaires in a randomized health education study to evaluate whether a substantial improvement in their well-being is achieved.
Study: NCT05434806

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Jarlsberg cheese
Description: Daly oral intake

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Jarlsberg cheese
Description: Daly oral intake
Study: NCT06020144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLL-018
Description: Oral tablets administered 2pieces BID for 52 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tofacitinib
Description: Oral tablets administered 1pieces BID for 52 weeks.
Study: NCT06250218

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video Interactive Guidance (VIG)
Description: Video interaction guidance (VIG) is a video feedback intervention through which a guider helps a client to enhance communication within relationships. The client is guided to analyse and reflect on video clips of their own interactions.
Study: NCT06456242

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CounsCM+MedCM (Health Rewards)
Description: Small financial incentives for completing quitline calls (CounsCM) plus small financial incentives for taking varenicline (MedCM).
Study: NCT05251376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levomethadone HCl
Description: One dose given orally on Day 8 of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: Daily usual oral dose given on Day 1 and Day 2 of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine Sulfate
Description: Administered daily and as needed from Day 3 of the study until subject back on usual daily methadone dose.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: x-ray
Description: Abdominal x-rays done at specific study timepoints to assess the location of the LYN-014.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: blood tests
Description: Done at specific timepoints throughout the study for PK (pharmacokinetics), genotyping and safety labs.
Study: NCT06327958

Intervention type: OTHER
Intervention: Cormack-Lehane (C&L)
Description: There is no distinguishing feature of the C\&L and POGO scores required to provide the best laryngoscopic view from other interventions in this or any other clinical trial.

Intervention type: OTHER
Intervention: Cormack-Lehane (C&L)
Description: There is no distinguishing feature of the C\&L and POGO scores required to provide the best laryngoscopic view from other interventions in this or any other clinical trial.
Study: NCT04099940

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality Avatar Therapy (VRAT)
Description: The Virtual Reality Avatar Therapy (VRAT) is a Cognitive Behavioral Intervention, delivered through Virtual Reality.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Avatar Therapy (VRAT)
Description: The Virtual Reality Avatar Therapy (VRAT) is a Cognitive Behavioral Intervention, delivered through Virtual Reality.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Assertiveness Training Program (ATP)
Description: The Assertiveness Training Program (ATP) is a Cognitive Behavioral Intervention, delivered as group therapy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assertiveness Training Program (ATP)
Description: The Assertiveness Training Program (ATP) is a Cognitive Behavioral Intervention, delivered as group therapy.
Study: NCT05936190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine IV
Description: Intravenous infusion rate of lidocaine is 2 mg/kg/min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Intravenous infusion rate of lidocaine is 1 mg/kg/min
Study: NCT06474468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A2102；Adebrelimab；Cisplatin
Description: Drug: SHR-A2102 Administration by intravenous infusion for a cycle of 3 weeks.~Drug: Adebrelimab Administration by intravenous infusion for a cycle of 3 weeks.~Drug: Cisplatin Administration by intravenous infusion for a cycle of 3 weeks.
Study: NCT06338527

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aromatherapy
Description: Lavender oil was used for aromatherapy intervention.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No intervention
Description: No aromatherapy intervention was performed during the period of the study.
Study: NCT05845398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCR-AUD
Description: DCR-A1203, the drug substance of DCR-AUD, is a synthetic double-stranded (hybridized duplex) RNA oligonucleotide conjugated to GalNAc ligands that enable specific hepatic access and update after subcutaneous administration. DCR-AUD is a sterile solution of DCR-A1203 at a concentration of 160 mg/mL in water for injection (WFI).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% saline for injection.
Study: NCT05781698

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalamine
Description: mesalamine is the cornerstone used for the treatment of mild to moderate ulcerative colitis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalamine
Description: mesalamine is the cornerstone used for the treatment of mild to moderate ulcerative colitis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenofibrate
Description: Fibrates, which are specific pharmacological agonists of PPARα, have been widely used in the treatment for hypercholesterolemia and hypertriglyceridemia
Study: NCT05293158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hepatect CP 50 I.E./ml infusion solution
Description: Application of i.v. (intravenously) HBIGs for ≥6-weeks:~Day (D) 0-7: 10.000 IU D14 until end-of-treatment: 10.000 IU once per week HBIGs will be given until LT/liver resection.
Study: NCT05400772

Intervention type: OTHER
Intervention: electromyographic device
Description: An 8-channel surface EMG system (Noraxon Telemyo DTS system, Scottsdale, USA) will be used to measure signals from muscles during surface electromyography measurements.
Study: NCT06327958

Intervention type: OTHER
Intervention: Cormack-Lehane (C&L)
Description: There is no distinguishing feature of the C\&L and POGO scores required to provide the best laryngoscopic view from other interventions in this or any other clinical trial.

Intervention type: OTHER
Intervention: POGO score
Description: There is no distinguishing feature of the C\&L and POGO scores required to provide the best laryngoscopic view from other interventions in this or any other clinical trial.

Intervention type: OTHER
Intervention: POGO score
Description: There is no distinguishing feature of the C\&L and POGO scores required to provide the best laryngoscopic view from other interventions in this or any other clinical trial.

Intervention type: OTHER
Intervention: POGO score
Description: There is no distinguishing feature of the C\&L and POGO scores required to provide the best laryngoscopic view from other interventions in this or any other clinical trial.
Study: NCT06229327

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: THERAPEUTICGAMES
Description: THERAPEUTICGAMES
Study: NCT06399250

Intervention type: OTHER
Intervention: meal service
Description: We're not subjecting patients to an intervention, as we will evaluate the current in-hospital meal service. As the three channel food concept is standard of care, we're not subjecting patients to dietary or behavioral changes. We will compare the data to an historic control.
Study: NCT05652387

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Father Inclusive Prenatal Care
Description: Pregnant and parenting couples participate in co-parenting and parenting education, and job skills and education readiness
Study: NCT04454242

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Expiratory muscle trainig
Description: This exercise will be used to strengthen forced expiratory muscles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Expiratory muscle trainig
Description: This exercise will be used to strengthen forced expiratory muscles.